Landos Biopharma(LABP) - 2023 Q4 - Annual Results

Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024 Exhibit 99.1 Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results Sufficient Cash to Fund Planned Operations into mid-2025 NEW YORK, March 21, 2024 –– Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos" or "the Company"), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business upd ...